[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355569-105":59,"doc-detail-355569-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-benefits-and-harms-of-screening-for-prostate-cancer-in-adults-aged-18-years-and-older-a-systematic-review","The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older - A Systematic Review","","Given ongoing uncertainty about the benefits and harms of prostate-specific antigen (PSA) screening, this systematic review updates evidence to inform guideline recommendations for adults aged ≥18 years in primary care. Searches covered randomized controlled trials and comparative observational studies evaluating PSA-based screening with or without MRI and other adjunct technologies (update through 24 July 2024). Four RCTs and one cohort study (17 articles) were included; results showed about 0.96 fewer prostate cancer deaths per 1000 over 9.5–22 years, with low evidence certainty, one trial reporting overdiagnosis, and overall variable harms.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-benefits-and-harms-of-screening-for-prostate-cancer-in-adults-aged-18-years-and-older-a-systematic-review/355569/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-benefits-and-harms-of-screening-for-prostate-cancer-in-adults-aged-18-years-and-older-a-systematic-review/355569.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the systematic review address?","Question",{"text":113,"@type":114},"It evaluates the benefits and harms of PSA screening for prostate cancer in adults aged 18 years and older, to inform screening guideline recommendations.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which study types and comparisons were included?",{"text":118,"@type":114},"The review included randomized controlled trials and comparative observational studies comparing PSA-based screening with no screening, with some studies evaluating MRI-targeted, risk-based testing.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the main findings on mortality benefit and harms?",{"text":122,"@type":114},"PSA screening was associated with about 0.96 fewer prostate cancer deaths per 1000 invited over 9.5–22 years, but the overall evidence certainty was low and at least one trial observed overdiagnosis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355569,1790520397,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26,"preview_page_count":19,"preview_urls":146},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Systematic Review  \nThe Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review  \nAlexandria Bennett 1, Niyati Vyas 1,*, Nicole Shaver 1, Faris Almoli 1, Taddele Kibret 1, Andrew Loblaw 2, Lisa Del Giudice 3, Xiaomei Yao 4,5, Becky Skidmore 6, Melissa Brouwers 1, Julian Little 1 and David Moher 1,7  \nReceived: 5 February 2026  \nRevised: 13 March 2026  \nAccepted: 28 March 2026  \nPublished: 31 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa,  \nOttawa, ON K1G 5Z3, Canada; [d.bennett@uottawa.ca](d.bennett@uottawa.ca) (A.B.); [nicole.shaver@uottawa.ca](nicole.shaver@uottawa.ca) (N.S.);  \n[almoli.faris@gmail.com](almoli.faris@gmail.com) (F.A.); [tkibr005@uottawa.ca](tkibr005@uottawa.ca) (T.K.); [melissa.brouwers@uottawa.ca](melissa.brouwers@uottawa.ca) (M.B.);  \n[jlittle@uottawa.ca](jlittle@uottawa.ca) (J.L.); [dmoher@ohri.ca](dmoher@ohri.ca) (D.M.)  \n2 Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON M4N 3M5, Canada; [andrew.loblaw@sunnybrook.ca](andrew.loblaw@sunnybrook.ca)  \n3 Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada; [lisa.delgiudice@sunnybrook.ca](lisa.delgiudice@sunnybrook.ca)  \n4 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8N 3Z5, Canada; [yaoxia@mcmaster.ca](yaoxia@mcmaster.ca)  \n5 Department of Oncology, McMaster University, Hamilton, ON L8V5C2, Canada  \n6 Independent Information Specialist, Ottawa, ON K1T 3Z2, Canada; [becky.skidmore.rls@gmail.com](becky.skidmore.rls@gmail.com)  \n7 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada  \n* [Correspondence: nvyas@uottawa.ca](Correspondence: nvyas@uottawa.ca)  \nSimple Summary  \nWith ongoing debate surrounding the benefits and harms of prostate-specific antigen (PSA) screening test for prostate cancer, we conducted this review to gather evidence that could help inform prostate cancer screening guideline recommendations for adults aged 18 years and older. We analyzed results from four large randomized clinical trials and one cohort study that compared PSA screening with no screening, including one study that evaluated risk-based testing with magnetic resonance imaging (MRI) . Overall, PSA screening was associated with about one fewer prostate cancer death per 1000 people invited for screening over 9.5–22 years, suggesting a small potential benefit. However, one trial also observed overdiagnosis, and the overall quality of the evidence across all outcomes was low, limiting the confidence in these findings. Further high-quality research is recommended, particularly on new MRI and risk-based screening strategies.  \nAbstract  \nGiven ongoing uncertainty about the benefits and harms of prostate-specific antigen (PSA) screening, this systematic review updates the evidence to inform guideline recommendations for adults aged ≥ 18 years in primary care. We searched multiple bibliographic databases from inception to 30 May 2022, with an update on 24 July 2024, for randomized controlled trials (RCTs) and comparative observational studies evaluating PSA-based screening with or without adjunctive technologies such as magnetic resonance imaging (MRI) . Studies were selected in duplicate, with data extraction and quality assessment verified by a second reviewer; risk of bias and evidence certainty were assessed using study design-specific tools and GRADE. Four RCTs and one cohort study (17 articles) were included: ERSPC, PLCO and CAP compared PSA screening with no screening, while STHLM3-MRI evaluated a risk-based test combined with MR","cbCaivUBMve3RCb6","https://ap.wps.com/l/cbCaivUBMve3RCb6","pdf",488611,24,"English","# Introduction\n## Evidence and study inclusion\n## Results summary\n## Evidence certainty and implications","[{\"question\":\"What question does the systematic review address?\",\"answer\":\"It evaluates the benefits and harms of PSA screening for prostate cancer in adults aged 18 years and older, to inform screening guideline recommendations.\"},{\"question\":\"Which study types and comparisons were included?\",\"answer\":\"The review included randomized controlled trials and comparative observational studies comparing PSA-based screening with no screening, with some studies evaluating MRI-targeted, risk-based testing.\"},{\"question\":\"What are the main findings on mortality benefit and harms?\",\"answer\":\"PSA screening was associated with about 0.96 fewer prostate cancer deaths per 1000 invited over 9.5–22 years, but the overall evidence certainty was low and at least one trial observed overdiagnosis.\"}]","The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older - A Systematic Review | PDF",1790119927,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6463d37a10ac3fc005631d35ae79b06f.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cc6fa981a0e932299197377dc4ba26a.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5317458ff22f6a91cb086cb6f2bcbc13.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/613fece903eaa2769c06bc1a2ab3ab9f.webp",980,1385]